Vaginal dryness is the most commonly recognized symptom of a broader condition called genitourinary syndrome of menopause (GSM) — the progressive changes that occur in the vaginal, vulvar, and urinary tissues as estrogen levels decline during and after menopause. GSM affects a majority of postmenopausal women, produces symptoms that worsen progressively over time without treatment, and responds well to therapy that is both effective and — in the case of local vaginal estrogen — has a very favorable safety profile.
Unlike vasomotor symptoms, which often improve over time in many women, GSM does not resolve spontaneously. The tissue changes of estrogen deficiency are progressive, and symptoms that begin as mild dryness can evolve into significant pain with intercourse, recurrent urinary tract infections, urinary urgency and frequency, and a quality of life impact that extends well beyond the bedroom. Treatment is most effective when started early — before tissue atrophy becomes advanced — but it is beneficial at any stage.
GSM produces a characteristic cluster of vulvovaginal and urinary symptoms that are all driven by the same underlying estrogen deficiency. Recognizing the full symptom picture helps explain why comprehensive treatment addresses all components together.
- Vaginal dryness — a persistent lack of natural moisture and lubrication
- Vaginal or vulvar burning, irritation, or soreness that is present at rest or worsened with activity
- Pain during sexual intercourse — often described as burning, tearing, or rawness with penetration
- Reduced sexual arousal and lubrication response during intimacy
- Vaginal tightness or narrowing that makes intercourse increasingly uncomfortable or impossible
- Post-coital spotting or light bleeding from fragile vaginal tissue
- Urinary urgency — a sudden compelling need to urinate
- Increased urinary frequency, including nocturia (waking at night to urinate)
- Recurrent urinary tract infections from changes in vaginal pH and urethral tissue
- Urinary burning or stinging — often mistaken for a UTI — from urethral atrophy
- Pelvic floor laxity and reduced vaginal wall support
Many women do not mention these symptoms because they assume they are an inevitable and untreatable part of aging. They are neither. They have effective treatments, and those treatments restore comfort in ways that significantly improve quality of life.
Most GSM symptoms are addressed through a scheduled appointment. Contact our office promptly if you experience:
- Any vaginal bleeding after 12 consecutive months without a period — postmenopausal bleeding always requires evaluation
- New or unusual vaginal lesions, sores, or ulcerations
- Vaginal symptoms accompanied by fever suggesting infection
The vaginal, vulvar, and lower urinary tract tissues are exquisitely sensitive to estrogen. As estrogen levels decline during perimenopause and drop further after menopause, these tissues undergo characteristic changes that produce the symptoms of GSM.
Vaginal Tissue Changes
Estrogen maintains the thickness, elasticity, and moisture of the vaginal epithelium. As estrogen declines, the vaginal epithelium thins — a process called atrophy — and loses its rugae (folds), becoming smooth, pale, and fragile. The vaginal pH rises from its premenopausal acidic state (which protects against infection) to a more alkaline range, increasing susceptibility to vaginal infections and disrupting the normal vaginal microbiome. Natural vaginal lubrication decreases as the vasocongestion response to arousal diminishes. The result is the dryness, burning, and pain with intercourse that characterize vaginal GSM.
Urethral and Bladder Tissue Changes
The urethra and bladder trigone are also estrogen-sensitive structures. Urethral atrophy produces thinning and reduced lubrication of the urethral lining, contributing to the burning with urination that is commonly mistaken for UTI symptoms. The altered vaginal pH and microbiome increase the likelihood of urinary tract infections in postmenopausal women. Bladder sensitivity increases as urethral and trigonal tissue loses estrogen support, contributing to urgency, frequency, and nocturia that are not driven by infection.
Why GSM Worsens Without Treatment
The progressive nature of GSM reflects the ongoing effects of estrogen deficiency on tissue dependent on estrogen for normal function. Unlike vasomotor symptoms, which may improve spontaneously as the body adapts to lower estrogen levels, the tissue atrophy of GSM is structural — and structural changes progress without hormonal support. Women who do not treat GSM often experience worsening symptoms over the postmenopausal years, including vaginal narrowing and stenosis that can make gynecologic examinations and intercourse progressively more difficult. This progressive worsening is one of the strongest arguments for early treatment.
Treatment for GSM is highly effective and ranges from over-the-counter measures through local and systemic hormonal therapy. The right approach depends on symptom severity, health history, and whether systemic vasomotor symptoms also require management.
Non-Prescription Measures
Regular use of vaginal moisturizers — applied 2-3 times per week — restores vaginal moisture and reduces the pH shift of atrophy. Lubricants used during intercourse reduce friction-related pain. These measures are appropriate adjuncts but are not sufficient to reverse tissue atrophy or address the urinary symptoms of GSM.
Local Vaginal Estrogen
Low-dose vaginal estrogen — available as creams, rings, tablets, or suppositories — delivers estrogen directly to the vaginal and urethral tissue at doses that produce minimal systemic absorption. It effectively reverses the tissue changes of GSM, restoring thickness, elasticity, and moisture. It is the most effective local treatment available and has an excellent safety profile appropriate even for many women with prior breast cancer — though this requires individual clinical discussion.
Systemic and Non-Estrogen Options
Systemic hormone therapy addresses GSM alongside vasomotor and other menopausal symptoms. Ospemifene (Osphena) is an oral non-estrogen option for dyspareunia from GSM. Prasterone (Intrarosa), a vaginal DHEA product, is another local non-estrogen option. The appropriate choice depends on whether systemic or local treatment is indicated based on the full symptom picture.
One of the most persistent myths in women’s health is that painful intercourse, vaginal dryness, and urinary urgency are simply what menopause means. They are not inevitable features of aging — they are treatable consequences of estrogen deficiency that respond well to targeted treatment.
Many women have never been told that local vaginal estrogen is safe, effective, and available — or that non-estrogen options exist for women who prefer to avoid hormones. The conversation that opens those options starts with a gynecologic evaluation that takes these symptoms seriously.
Dr. Ramona D. Andrei and the team at Lapeer Women’s Health are here for that conversation — at both our Lapeer and Rochester Hills offices, without a referral required.
Vaginal Dryness in Menopause
Our team at Lapeer Women’s Health offers effective local and systemic options for GSM at both our Lapeer and Rochester Hills offices. No referral required.
Schedule a Gynecologic VisitThe information on this page is intended for educational purposes only and does not constitute medical advice. Content reviewed by Dr. Ramona D. Andrei, MD PhD FACOG.
Gynecologic care for women of every age
Lapeer Women’s Health — Rochester Hills
2710 S Rochester Rd, Suite 2
Rochester Hills, MI 48307
Serving patients in Lapeer, Rochester Hills, and surrounding communities throughout Southeast Michigan.